AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 39589719 — intervention group
Group type: EXPERIMENTAL
Intervention: delandistrogene moxeparvovec
Number of subjects: 0
Study 39589721 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-delivered brief behavioral treatment for insomnia (BBTI)
Number of subjects: 132
Study 39589721 — intervention group
Group type: COMPARATOR
Intervention: Healthy eating attention control group
Number of subjects: 132
Study 39589730 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunosuppressive therapies
Number of subjects: 73
Study 39589730 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral corticosteroids
Number of subjects: 73
Study 39589730 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer remission
Number of subjects: 73
Study 39589730 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger age
Number of subjects: 73
Study 39589730 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained cancer activity
Number of subjects: 73
Study 39589730 — intervention group
Group type: EXPERIMENTAL
Intervention: Male sex
Number of subjects: 73
Study 39589730 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 73
Study 39589730 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained DM activity
Number of subjects: 73
Study 39589786 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile app-based behavioral intervention (DRIVEN) for job seekers over 6 weeks, including scheduled video counseling sessions with a job coach.
Number of subjects: 150
Study 39589786 — intervention group
Group type: COMPARATOR
Intervention: Job seeking as usual (control group).
Number of subjects: 150
Study 39589824 — intervention group
Group type: EXPERIMENTAL
Intervention: gp42-IgG antibody titers
Number of subjects: 75481
Study 39590165 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide and Dexamethasone (Len/Dex) followed by Donor Lymphocyte Infusions (DLIs)
Number of subjects: 22
Study 39590221 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fatigue leg extension exercise
Number of subjects: 0
Study 39590221 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fatigue leg extension exercise
Number of subjects: 0
Study 39590221 — intervention group
Group type: COMPARATOR
Intervention: Control condition (quiet rest)
Number of subjects: 0
Study 39590559 — intervention group
Group type: EXPERIMENTAL
Intervention: Stair-climbing exercise (STAIR)
Number of subjects: 46
Study 39590559 — intervention group
Group type: COMPARATOR
Intervention: Machine-based resistance training (RT)
Number of subjects: 46
Study 39591190 — intervention group
Group type: EXPERIMENTAL
Intervention: Prime-2-CoV_Beta vaccine
Number of subjects: 60
Study 39591365 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous adipose-derived regenerative cells (ADRCs) (4.20×10^7 ± 1.75×10^7 cells) and 30-cc lipotransfer
Number of subjects: 80
Study 39591365 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 80
Study 39591365 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous adipose-derived regenerative cells (ADRCs) and lipotransfer
Number of subjects: 80
Study 39591420 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication Coordinator intervention with medication review and suggested amendments documented in electronic discharge letter sent to GP
Number of subjects: 70
Study 39591420 — intervention group
Group type: COMPARATOR
Intervention: Standard care by ward staff
Number of subjects: 70
Study 39591420 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication Coordinator intervention
Number of subjects: 70
Study 39591454 — intervention group
Group type: COMPARATOR
Intervention: Albendazole alone
Number of subjects: 0
Study 39591454 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole plus ivermectin
Number of subjects: 0
Study 39591551 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenvatinib 20 mg once daily plus Pembrolizumab 200 mg once every 3 weeks
Number of subjects: 842
Study 39591551 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (Paclitaxel 175 mg/m2)
Number of subjects: 842
Study 39591972 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitors (ICIs)
Number of subjects: 0
Study 39592015 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic media use
Number of subjects: 441
Study 39592213 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphatidylethanol (PEth) measurement for alcohol use stratification
Number of subjects: 355
Study 39592213 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol consumption of two or more standard drinks per day
Number of subjects: 355
Study 39592214 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic hip surgery
Number of subjects: 222
Study 39592214 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy
Number of subjects: 222
Study 39592365 — intervention group
Group type: EXPERIMENTAL
Intervention: Driving pressure-limiting strategy
Number of subjects: 198
Study 39592365 — intervention group
Group type: COMPARATOR
Intervention: Low PEEP strategy
Number of subjects: 198
Study 39592468 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic supplementation (including L. rhamnosus DSM 32550, Humiome® L. plantarum DSM 34532, B. lactis DSM 32269, B. longum DSM 32946, fructooligosaccharides and zinc)
Number of subjects: 26
Study 39592468 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic supplementation
Number of subjects: 26
Study 39592468 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 39592501 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic imaging study for detection rates in early BCR of prostate cancer after radical surgery or radiotherapy.
Number of subjects: 50
Study 39592514 — intervention group
Group type: EXPERIMENTAL
Intervention: High resuscitation table positioning
Number of subjects: 28
Study 39592514 — intervention group
Group type: COMPARATOR
Intervention: Low resuscitation table positioning
Number of subjects: 28
Study 39592547 — intervention group
Group type: EXPERIMENTAL
Intervention: FIL200 (200 mg once daily)
Number of subjects: 285
Study 39592547 — intervention group
Group type: EXPERIMENTAL
Intervention: FIL100 (100 mg once daily)
Number of subjects: 285
Study 39592547 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab (40 mg biweekly)
Number of subjects: 285
Study 39592547 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 285
Study 39592624 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib plus letrozole
Number of subjects: 0
Study 39592626 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergen-specific immunotherapy (AIT)
Number of subjects: 0
Study 39592626 — intervention group
Group type: COMPARATOR
Intervention: Venom allergy patients (VAP)
Number of subjects: 0
Study 39592626 — intervention group
Group type: COMPARATOR
Intervention: Pollen-allergic and healthy controls
Number of subjects: 0
Study 39592888 — intervention group
Group type: EXPERIMENTAL
Intervention: BAT4406F (escalated doses ranging from 20 to 750 mg)
Number of subjects: 15
Study 39593072 — intervention group
Group type: EXPERIMENTAL
Intervention: RUTF plus prebiotics
Number of subjects: 174
Study 39593072 — intervention group
Group type: COMPARATOR
Intervention: RUTF plus starch
Number of subjects: 174
Study 39593072 — intervention group
Group type: COMPARATOR
Intervention: Starch as placebo
Number of subjects: 174
Study 39593091 — intervention group
Group type: EXPERIMENTAL
Intervention: Carrageenan
Number of subjects: 20
Study 39593091 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 39593101 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotics-assisted therapy (RAT) at home for 30 consecutive days after 2 therapist-supervised clinic onboarding sessions.
Number of subjects: 12
Study 39593191 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg
Number of subjects: 83
Study 39593191 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 10 mg
Number of subjects: 83
Study 39593191 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 5 mg
Number of subjects: 83
Study 39593191 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 2.5 mg
Number of subjects: 83
Study 39593191 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 1 mg
Number of subjects: 83
Study 39593191 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study 39593197 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep Deprivation (SD)
Number of subjects: 20
Study 39593197 — intervention group
Group type: COMPARATOR
Intervention: Normal sleep night
Number of subjects: 20
Study 39593225 — intervention group
Group type: EXPERIMENTAL
Intervention: Qigong Wuqinxi exercise for 50 minutes three times a week for 12 weeks
Number of subjects: 63
Study 39593225 — intervention group
Group type: COMPARATOR
Intervention: Normal daily routine (control group)
Number of subjects: 63
Study 39593435 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Thai massage (TTM)
Number of subjects: 62
Study 39593435 — intervention group
Group type: COMPARATOR
Intervention: SUS group (control)
Number of subjects: 62
Study 39593477 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradialytic aerobic exercise on an adapted stationary exercise bike, three times per week for three months.
Number of subjects: 33
Study 39593477 — intervention group
Group type: COMPARATOR
Intervention: Control group (without exercise) during the first three months, then switched to exercise after washout period.
Number of subjects: 33
Study 39593519 — intervention group
Group type: EXPERIMENTAL
Intervention: Newly diagnosed hyperthyroidism (NDH)
Number of subjects: 16
Study 39593519 — intervention group
Group type: EXPERIMENTAL
Intervention: Euthyroid state
Number of subjects: 16
Study 39593519 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 16
Study 39593526 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin-A
Number of subjects: 60
Study 39593526 — intervention group
Group type: COMPARATOR
Intervention: Occlusal appliance
Number of subjects: 60
Study 39593537 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical therapy protocol + active cervical postural treatment for 4 weeks
Number of subjects: 0
Study 39593537 — intervention group
Group type: COMPARATOR
Intervention: Active cervical postural treatment for 4 weeks
Number of subjects: 0
Study 39593541 — intervention group
Group type: EXPERIMENTAL
Intervention: Reformer Pilates exercise (6-week program, 45 min/twice per week)
Number of subjects: 44
Study 39593541 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise program)
Number of subjects: 44
Study 39593566 — intervention group
Group type: EXPERIMENTAL
Intervention: Feldenkrais method (16 sessions of sensorimotor training)
Number of subjects: 44
Study 39594812 — intervention group
Group type: EXPERIMENTAL
Intervention: Roflumilast in combination with R-CHOP (Ro+R-CHOP)
Number of subjects: 0
Study 39595811 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 0
Study 39595811 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 39595863 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodic tDCS combined with motor activity (MotA)
Number of subjects: 23
Study 39595863 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodic tDCS combined with cognitive activity (CogA)
Number of subjects: 23
Study 39595863 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS combined with motor activity (MotS)
Number of subjects: 23
Study 39595863 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS combined with cognitive activity (CogS)
Number of subjects: 23
Study 39596792 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled Colistin via nebulizer type A
Number of subjects: 0
Study 39596792 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled Colistin via nebulizer type B
Number of subjects: 0
Study 39596792 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 39597902 — intervention group
Group type: EXPERIMENTAL
Intervention: Tunnel Technique and Subepithelial Connective Tissue Graft with Cross-Linked Hyaluronic Acid
Number of subjects: 0
Study 39597902 — intervention group
Group type: EXPERIMENTAL
Intervention: Tunnel Technique and Subepithelial Connective Tissue Graft without Cross-Linked Hyaluronic Acid
Number of subjects: 0
Study 39597902 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 39599585 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcifediol 75 µg
Number of subjects: 398
Study 39599585 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcifediol 100 µg
Number of subjects: 398
Study 39599585 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 398
Study 39599686 — intervention group
Group type: EXPERIMENTAL
Intervention: Carnosine supplementation (2 g/day for 14 weeks)
Number of subjects: 49
Study 39599686 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 39599724 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component nutritional intervention combining digital interactive tools, hands-on educational materials, and healthy snacks
Number of subjects: 480
Study 39599724 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 480
Study 39599745 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged Water-Only Fasting followed by a Whole-Plant-Food Diet
Number of subjects: 0
Study 39599746 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (ω3) supplementation (300 mg capsules, 2 daily for 9 weeks)
Number of subjects: 88
Study 39599746 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D (VitD) supplementation (50,000 IU tablet, 1 weekly for 9 weeks)
Number of subjects: 88
Study 39599746 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (ω3) + Vitamin D (VitD) supplementation
Number of subjects: 88
Study 39599746 — intervention group
Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 88
Study 39599964 — intervention group
Group type: EXPERIMENTAL
Intervention: Action Observation Therapy (AOT)
Number of subjects: 34
Study 39599964 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional swallowing therapy without videos)
Number of subjects: 34
Study 39600492 — intervention group
Group type: EXPERIMENTAL
Intervention: D-dimer in patients with acute MVT (n=73)
Number of subjects: 360
Study 39600492 — intervention group
Group type: COMPARATOR
Intervention: D-dimer in non-AMI patients (n=287)
Number of subjects: 360
Study 39600492 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated D-dimer
Number of subjects: 360
Study 39600565 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine ultrasound-guided suprascapular nerve block combined with home-based rotator cuff exercises
Number of subjects: 0
Study 39600565 — intervention group
Group type: COMPARATOR
Intervention: Saline ultrasound-guided suprascapular nerve block combined with home-based rotator cuff exercises
Number of subjects: 0
Study 39600654 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle fatigue protocol
Number of subjects: 24
Study 39600654 — intervention group
Group type: COMPARATOR
Intervention: Activation
Number of subjects: 24
Study 39600654 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 24
Study 39600719 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized nutritional support
Number of subjects: 238
Study 39600719 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 238
Study 39600719 — intervention group
Group type: EXPERIMENTAL
Intervention: Low nitrotyrosine and high DOPA and dopamine levels
Number of subjects: 238
Study 39600968 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-cTnT levels
Number of subjects: 330
Study 39601025 — intervention group
Group type: EXPERIMENTAL
Intervention: Philips 66 technique integrated into Case-Based Learning (CBL)
Number of subjects: 60
Study 39601025 — intervention group
Group type: COMPARATOR
Intervention: Conventional approaches (Control)
Number of subjects: 60
Study 39601078 — intervention group
Group type: EXPERIMENTAL
Intervention: Molnupiravir (800 mg)
Number of subjects: 0
Study 39601078 — intervention group
Group type: COMPARATOR
Intervention: Healthy mean-matched controls
Number of subjects: 0
Study 39601078 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with moderate hepatic or severe renal impairment
Number of subjects: 0
Study 39601078 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with severe renal impairment
Number of subjects: 0
Study 39601078 — intervention group
Group type: EXPERIMENTAL
Intervention: All participants
Number of subjects: 0
Study 39601121 — intervention group
Group type: EXPERIMENTAL
Intervention: Venous-TD
Number of subjects: 61
Study 39601121 — intervention group
Group type: COMPARATOR
Intervention: Angioguard (control)
Number of subjects: 61
Study 39601122 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed Field Ablation (PFA) as first-line therapy
Number of subjects: 1091
Study 39601122 — intervention group
Group type: COMPARATOR
Intervention: Pulsed Field Ablation (PFA) after prior class I/III AAD therapy
Number of subjects: 1091
Study 39601214 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical shock treatment (5 milliamps)
Number of subjects: 90
Study 39601214 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 90
Study 39601265 — intervention group
Group type: EXPERIMENTAL
Intervention: Clesrovimab (100 mg for full-term, 20, 50, 75, or 100 mg for preterm)
Number of subjects: 183
Study 39601265 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 183
Study 39601265 — intervention group
Group type: EXPERIMENTAL
Intervention: Clesrovimab
Number of subjects: 183
Study 39601271 — intervention group
Group type: EXPERIMENTAL
Intervention: Center M intervention (4 one-hour weekly group telehealth sessions)
Number of subjects: 99
Study 39601296 — intervention group
Group type: EXPERIMENTAL
Intervention: Sub-ulcer foam sclerotherapy and compression therapy
Number of subjects: 23
Study 39601296 — intervention group
Group type: COMPARATOR
Intervention: Compression therapy only
Number of subjects: 23
Study 39601324 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound (EUS)
Number of subjects: 0
Study 39601324 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS-guided portal pressure gradient (PPG) measurement
Number of subjects: 0
Study 39601324 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS
Number of subjects: 0
Study 39601354 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intake of individuals with PSC compared to Nordic nutrition recommendations 2023 (NNR2023)
Number of subjects: 120
Study 39601354 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary quality evaluated using an index developed by the National Food Agency in Sweden
Number of subjects: 120
Study 39601394 — intervention group
Group type: EXPERIMENTAL
Intervention: FFR-guided PCI
Number of subjects: 0
Study 39601394 — intervention group
Group type: COMPARATOR
Intervention: IVUS-guided PCI
Number of subjects: 0
Study 39601393 — intervention group
Group type: EXPERIMENTAL
Intervention: Pivot-balloon procedure
Number of subjects: 7
Study 39601397 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 888
Study 39601420 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with IBS
Number of subjects: 646
Study 39601420 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 646
Study 39601687 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-coated balloon (CVT-DCB)
Number of subjects: 51
Study 39601743 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel monotherapy for normal, rapid, or ultrarapid CYP2C19 metabolizers (n=69)
Number of subjects: 100
Study 39601743 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel or ticagrelor monotherapy for loss-of-function allele carriers (n=29)
Number of subjects: 100
Study 39601743 — intervention group
Group type: COMPARATOR
Intervention: Dual antiplatelet therapy (clopidogrel and aspirin) for all patients initially
Number of subjects: 100
Study 39601809 — intervention group
Group type: EXPERIMENTAL
Intervention: Assisted group (active pushing during cesarean delivery)
Number of subjects: 100
Study 39601809 — intervention group
Group type: COMPARATOR
Intervention: Conventional group (traditional cesarean delivery without maternal pushing)
Number of subjects: 100
Study 39601809 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study 39601827 — intervention group
Group type: EXPERIMENTAL
Intervention: Excitation of the bottom-up pathways at the lateral elbow muscles (intervention group)
Number of subjects: 55
Study 39601827 — intervention group
Group type: COMPARATOR
Intervention: Control group (pressure pain threshold determined at multiple lateral elbow muscles)
Number of subjects: 55
Study 39601827 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (excitation of bottom-up pathways)
Number of subjects: 55
Study 39601827 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall comparison between groups
Number of subjects: 55
Study 39601933 — intervention group
Group type: EXPERIMENTAL
Intervention: PharmaCAP intervention (clinical pharmacist-led medication review, pain assessment, education, and counseling)
Number of subjects: 92
Study 39601933 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 92
Study 39601932 — intervention group
Group type: EXPERIMENTAL
Intervention: RAMTAKE-supported training
Number of subjects: 40
Study 39601932 — intervention group
Group type: COMPARATOR
Intervention: Routine training in the hospital
Number of subjects: 40
Study 39601981 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 h/12 h intravenous infusion of Cyclosporin A (CsA)
Number of subjects: 31
Study 39601981 — intervention group
Group type: COMPARATOR
Intervention: 22 h continuous infusion of Cyclosporin A (CsA)
Number of subjects: 31
Study 39602111 — intervention group
Group type: EXPERIMENTAL
Intervention: Deucravacitinib, 6 mg once daily
Number of subjects: 1519
Study 39602120 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory care
Number of subjects: 105
Study 39602120 — intervention group
Group type: COMPARATOR
Intervention: Overnight hospital surveillance
Number of subjects: 105
Study 39602139 — intervention group
Group type: EXPERIMENTAL
Intervention: Nemolizumab (30 mg or 60 mg depending on baseline weight) administered every 4 weeks for 24 weeks
Number of subjects: 286
Study 39602143 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic drain
Number of subjects: 390